Bursa Postgraduate Hospital
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Anti Factor Xa level
研究概览
简要总结
The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.
详细描述
The study included 65 people who underwent contrast computerized tomography (CT). The study patients were divided into 4 groups. Patients in group 1 were using rivaroxaban (20 patients), patients in group 2 were using apixaban (20 patients), patients in group 3 were using edoxaban (20 patients), and group 4 was the control group (5 volunteers). Iohexol (60 ml) was used as a contrast agent. Two tubes were used to collect 2 ml of blood from the patients at 4 hours after the drug dose (rivaroxaban, apixaban, or edoxaban) and 1 hour after the contrast CT (CT was performed 3 hours after the drug was taken). In the control group, at any time and 1 hour after contrast CT, 2 tubes of 2 ml of blood were collected. The anticoagulant properties of rivaroxaban, apixaban, and edoxaban were evaluated using anti-factor Xa levels.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •the use of oral factor Xa inhibitors (patients with nonvalvular AF and CHA2DS2-VASc Score ≥2),
- •age of 21-80 years,
- •no contraindications for anticoagulation use,
- •GFR greater than 30,
- •volunteering to participate in the study, and
- •patients who needed to use contrast agent (iohexol) for CT examination. -
排除标准
- •coagulopathy,
- •severe hepatic insufficiency,
- •chronic systemic or inflammatory diseases,
- •patients lighter than 60 kg,
- •malignancy,
- •creatinine value above 1.5 mg/dl, and
- •not providing consent to participate in the study -
研究组 & 干预措施
rivaroxaban group
20 rivaroxaban using patients
干预措施: computerized tomography (Drug)
apixaban group
20 apixaban using patients
干预措施: computerized tomography (Drug)
edoxaban group
20 edoxaban using patients
干预措施: computerized tomography (Drug)
control group
5 control group patients
干预措施: computerized tomography (Drug)
结局指标
主要结局
Anti Factor Xa level
时间窗: 14 days
次要结局
未报告次要终点
研究者
Hasan ARI
Professor Doctor
Bursa Postgraduate Hospital